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Abstract: 
Hematopoiesis is highly regulated through cytokine-induced stimulation of multiple signal transduction 
pathways in order to mediate appropriate differentiation and proliferation of specific progenitor populations. 
Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple 
downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell 
populations.  Genomic alterations of the FLT3 gene leads to autonomous receptor activation, dysregulation of 
FLT3 signal transduction pathways, contributes to myeloid pathogenesis, and have been linked to response to 
therapy and clinical outcome. Exploring the mechanisms by which these FLT3 alterations lead to dysregulated 
proliferation would provide a better understanding of the molecular pathogenesis of AML and may provide 
insights into potential therapeutic interventions. 
 
Structure and Function of FLT3 
FLT3, a receptor tyrosine kinase (RTK), is a membrane-bound receptor with an intrinsic tyrosine kinase 
domain.  FLT3 is composed of a immunoglobulin-like extracellular ligand-binding domain, a transmembrane 
domain, a juxtamembrane dimerization domain and a highly conserved intracellular kinase domain interrupted 
by a kinase insert.  FLT3 belongs to the class III subfamily of RTKs which include structurally similar members 
such as c-FMS, c-KIT and PDGF receptor.    FLT3 is primarily expressed on committed myeloid and lymphoid 
progenitors(1, 2) with variable expression in the more mature monocytic lineage. FLT3 expression has been 
described in lymphohematopoietic organs such as the liver, spleen, thymus, and placenta. (3, 4)  
In the un-stimulated state, FLT3 receptor exists in a monomeric, unphosphorylated form with an inactive kinase 
moiety.  Upon interaction of the receptor with FLT ligand (FL), the receptor undergoes a conformational 
change, resulting in the unfolding of the receptor and the exposure of the dimerization domain, allowing 
receptor-receptor dimerization to take place. This receptor dimerization is the prelude to the activation of the 
tyrosine kinase enzyme, leading to phosphorylation of various sites in the intracellular domain.  The activated 
receptor recruits a number of proteins in the cytoplasm to form a complex of protein-protein interactions in the 
intracellular domain. SHC proteins, GRB2, GRB2-associated binder 2 (GAB2), SHIP, CBL, and CBLB (CBLB 
related protein) are a few of the many adaptor proteins that interact with the activated FLT3 receptor .(5-10) As 
each protein binds to the complex, it becomes activated in turn, resulting in a cascade of phosphorylation 
reactions that culminates in activation of a number of secondary mediators, including MAP kinase, STAT and 
AKT/PI3 kinase signal transduction pathways.  Once activated, these activated mediators are chaperoned to the 
nuclear interphase by HSP90, where the message is translocated to the nucleus.  In the nucleus, these 
transcriptional mediators trigger a series of events culminating in regulation of cell differentiation, proliferation 
apoptosis, and cell survival (Figure 1). 
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FLT3 Function in Normal and Malignant Hematopoiesis: 
FLT3 activation regulates a number of cellular process (e.g. phospholipid metabolism, transcription, 
proliferation, and apoptosis), and through these processes, FLT3 activation plays a critical role in governing 
normal hematopoiesis and cellular growth.(11, 12)  Optimum FLT3 function requires the coordinated effort of 
other  growth factors such as SCF, and IL3.(12, 13)  Combinations of FL and other growth factors have been 
found to promote proliferation of primitive hematopoietic progenitor cells as well as more committed early 
myeloid and lymphoid precursors.(11, 12, 14, 15)  FL stimulation appears to mediate differentiation of the early 
progenitors, where exposure of the hematopoietic progenitors to FL, leads to monocytic differentiation, without 
significant proliferation.(12) Although FLT3 knockout mice have a subtle phenotype, (16)  mice transplanted 
with FLT3 knock out cells displayed a more global disruption of hamatopoiesis.(16)  In addition, if both KIT 
and FLT3 were knocked out, mice developed severe, life-limiting hematopoietic deficiencies.  Thus, the in vitro 
data and murine knockout models confirm a major role for FLT3 in normal hematopoiesis, especially in times 
of hematopoietic stress.    
Expression of FLT3 has been evaluated in hematologic malignancies.  The majority of B-cell ALL and 
AML blasts (> 90%) express FLT3 at various leves.(1)  Although less frequently and with more variable 
expression levels, FLT3 receptors are also expressed in other hematopoietic malignancies, including 
myelodysplasia (MDS), chronic myeloid leukemia (CML), T-cell ALL, and chronic lymphocyctic leukemia 
(CLL).(1)  Recent data suggest that very high levels of FLT3-WT receptors may promote constitutive activation 
of the wild-type receptor in malignant cells,(17) and other studies have found that increased FLT3-WT 
expression in leukemic blasts may be associated with a worse prognosis (18)  
 
Genomic Alteration of FLT3 in AML 
Early studies evaluating function altering genomic alterations in FLT3 gene identified 2 distinct mutations in 
juxtamembrand and kinase domains of the FLT3 gene.  Internal tandem duplication of the juxtamembrane 
domain coding sequence in FLT3 (FLT3/ITD) was identified in a high proportion of patients with AML.(19)  
Additional studies identified missence mutations in the activation loop of the tyrosine kinase domain of FLT3 
(FLT3 Activation loop mutation, FLT3/ALM).(20)   
 
FLT3 internal tandem duplications (FLT3/ITD):  These mutations are the result of a segmental duplication of a 
fragment within the juxtamembrane domain coding region (encoded by exons 14 and 15) of FLT3, and are the 
most common type mutation in hematologic malignancies, occurring in CML (5-10%), MDS (5 – 10%), and 
AML (15 – 35%) patients.(19, 21-29)   Prevalence of FLT3/ITD is highly age dependent, where it is rare in 
infant AML, and the prevalence increases in a step-wise manner to 5-10% in age 5-10, 20% in young adults and 
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>35% in AML patients older than 55 years. (28)  There is also considerable variability in size, and region of 
ITD involvement (ranging from 3 to >400 basepairs).(19, 30, 31) 
 
In vitro studies have demonstrated that FLT3/ITDs promote ligand-independent receptor dimerization, leading 
to autonomous phosphoyrylation and constitutive activation of the receptor, culminating in cytokine 
independent cellular proliferation.(21, 32-35) The specific mechanism by which FLT3/ITDs lead to auto-
dimerization is unknown, however, JM domain is thought to act as a negative regulatory domain by preventing 
activation loop from adopting active conformation, thus maintaining the receptor in an auto-inhibited state.   
Three dimensional structure analysis of the FLT3 receptor suggests that segmental duplication of the JM 
domain may disrupt steric hindrance that normally prevent auto-dimerization, allowing receptor-receptor 
interaction to take place. Similar “repulsive” forces have been described in JM domains of other receptors (e.g. 
KIT), and disruption of the JM domain in other receptors also promotes constitutive activation.(36, 37) Most 
likely, the dimerization of the FLT3/ITD receptors causes additional structural changes in the receptor to a more 
relaxed confirmation, exposing the phosphoryl acceptor sites within the TKDs and promoting 
autophosphorylation.(38)  
 FLT3/ITDs are thought to promote proliferation via the activation of multiple signaling pathways 
including RAS/MAPK, STAT and the AKT/PI3 kinase pathways.     Mizuki et al. demonstrated that cytokine 
independent cellular proliferation of FLT3/ITD transduced cells was mediated by RAS and STAT5 
pathways.(39) Demonstration of STAT5 activation in FLT3/ITD highlighted that some of the effects of 
FLT3/ITDs are unique to the mutated receptor, where in contrast to FLT3/ITD, ligand-induced FLT3-WT 
activation does not lead to STAT5 activation and no STAT5 DNA binding.(34) Subsequent studies have 
determined that codons T589 and T591 within the JM of the mutated FLT3 receptor may account for some of 
the STAT5 activation in cells harboring FLT3/ITDs.(40)  Other studies have demonstrated that in addition to 
RAS and STAT pathways, FLT3/ITDs constitutively phosphorylate and activate AKT, and that ligand 
independent growth requires this aberrant AKT activation by FLT3/ITDs, such that the ligand independent 
growth is reversed if AKT activation is blocked.(41)  
FLT3 Activation Loop Mutations (FLT3/ALM):  Missense point mutations within the activation loop of 
the FLT3 kinase domain (FLT3/ALM) are the second type of FLT3 mutation.(20, 25, 28, 42-45)  These 
mutations are also referred to as FLT3 tyrosine kinase domain mutations (FLT3/TKD).  FLT3/ALMs have been 
found in the malignant cells from patients with CML (~1%), ALL (1-3%), MDS (2-5%), and AML (5-
10%).(20, 25, 28, 46)  Since patients seldom harbor both a FLT3/ITD and FLT3/ALM,(47) a high percentage of 
AML patients (25 – 45%) will have at least one type of FLT3 mutation, making FLT3 mutations one of the 
most common genetic abnormalities in AML.(25, 28, 43, 48)  In contrast to the age-dependent increase in the 
prevalence of FLT3/ITD, FLT3/ALM prevalence appears to be constant across all age ranges.(28)  The majority 
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of the FLT3/ALMs occur in codons 835 with a change of an aspartic acid to tyrosine (D835Y), however, other 
point mutations, deletions, and insertions within codon D835 and its surrounding codons have been 
described.(20, 25, 44, 45, 49)  
 
Although FLT3/ALM promote autophosphorylation of the receptor, constitutive receptor activation, and ligand-
independent proliferation, similar to that of FLT3/ITD, (20, 21, 32-34, 49) there are significant biological 
differences between the two types of FLT3 mutations.(40, 50-54) FLT3/ITDs and FLT3/ALMs appear to 
promote activation of different downstream effectors,(50) and different biological responses.  Animal studies 
have demonstrated that mice harboring FLT3/ITDs primarily develop an oligoclonal myeloproliferative 
disorder, while mice harboring FLT3/ALM are more likely to develop oligoclonal lymphoid disorders.(51)   
 
Clinical Significance of FLT3 Mutations 
 Identification of FLT3 mutations in AML has yielded novel approaches to the management of this 
disease.   Whether it is through their utility as prognostic factors or their use as a target for directed therapies, 
FLT3 mutations have provided clinicians with novel therapeutic options for a large subset of AML patients.  
We will specifically address the prognostic significance of the FLT3 mutations and their role in risk-based 
therapy, including hematopoietic cell transplantation (HCT) for AML patients with FLT3 mutations.  
Furthermore, we will review the available data on the efficacy in AML patients of small molecule inhibitors 
against FLT3 mutations. 
 
Prognostic Significance of FLT3/ITD:  Kiyoi et al. described FLT3/ITDs in AML, finding that approximately 
25% of AML patients harbored these mutations.(26)  In their study, AML patients with FLT3/ITDs had a higher 
diagnostic WBC, and the FLT3/ITDs were associated with normal cytogenetics.  Although there was no 
significant difference in complete response (CR) rates between patients with and without FLT3/ITDs, those 
patients with FLT3/ITDs had a significantly higher relapse rate (RR) and worse overall survival (OS).(26)    
Specifically, in younger adult patients (< 60 years old), FLT3/ITDs was the strongest predictor of outcome.(26)    
Subsequent larger studies have confirmed that presence of FLT3/ITD is an independent prognostic factor for 
relapse and poor outcome in AML.(24, 25, 27)  Kottaridis et al. examined the prevalence and prognostic 
significance of FLT3/ITDs in a cohort of over adult 850 patients.(27)  These investigators found a FLT3/ITD 
prevalence of 27%.  Their study confirmed that FLT3/ITDs were associated with leukocytosis and normal 
cytogenetics. In their study, AML patients with FLT3/ITDs had a lower remission rate, higher relapse rate and 
worse survival. Multivariate analyses controlling for other prognostic factors found that FLT3/ITDs were the 
most significant prognostic factor with respect to RR and disease free survival (DFS).(27)   
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 Other studies have confirmed the prognostic significance of FLT3/ITD in large adult and pediatric AML 
trials.(24, 28, 55)   In these studies survival for patients with FLT3/ITD was 20-30% compared to 50% for those 
without FLT3/ITD.  They also made an observation that allelic variation (mutant to wild type ratio) observed in 
patients with FLT3/ITD appeared to influence outcome.(28, 55) Evaluation of various thresholds of FLT3/ITD 
allelic ratio (ITD-AR) established an allelic ratio threshold that demarcated patients with FLT3/ITD at high risk 
of relapse from those expected to have a more favorable outcome, demonstrating that it is not merely the 
presence of FLT3/ITD, but the allelic variation that determines clinical outcome.(28)  Similar work in other 
studies have demonstrated difference in clinical outcome for those with differing allelic ratios.(55, 56) 
 
Clinical Significance of FLT3/ALM:  Shortly after FLT3/ITD was recognized, the presence of FLT3 
activation loop domain mutations (FLT3-ALM) were reported in 7% of patients with AML and their presence 
was associated with poor outcome.(20)  More thorough evaluation of large cohort of patients have more fully 
defined the prevalence and prognostic significance of FLT3/ALM in pediatric and adult AML.  Prevalence of 
FLT3/ALM is 6-8%, regardless of age and the presence of FLT3/ALM and FLT3/ITD appears to be mutually 
exclusive.(28, 57)  These studies further demonstrated that presence of FLT3/ALM is not associated with 
leukocytosis, and in contrast to FLT3/ITD, those with FLT3/ALM do not have adverse outcome. As biologic 
studies have previously demonstrated functional differences between the FLT3/ITD and FLT3/ALM, such 
clinical differences between the two types of FLT3 mutations are not surprising.(50, 51)  Reviewing the clinical 
outcome data in the context of FLT3/ITD allelic variation and FLT3/ALM, one would conclude that factors in 
addition to the presence of FLT3 mutation or activation of the receptor impact biology of the disease and in fact 
other structural alterations associated with FLT3/ITD may impact disease progression. 
 
Underlying Mechanism of Allelic Variation in FLT3/ITD: 
As variation of allelic ratio is associated with clinical outcome, delineation of the underlying mechanism of the 
allelic variation may provide insight into the pathogenesis of AML and guide therapeutic intervention.  Initial 
evaluation of homozygous FLT3/ITD by STR primers revealed loss of heterozygosity (LOH) as a contributor to 
the disease pathogenesis in FLT3/ITD-positive AML.(58)  A study by Whitman et al. substantiated the presence 
of LOH in a cohort of FLT3/ITD AML patients, and demonstrated that presence of LOH was associated with 
high risk disease.(59)   Novel high throughput methods have allowed more comprehensive evaluation of the 
LOH in patients with FLT3/ITD.  Whole genome evaluation of copy number and LOH alterations by SNP/CGH 
array technology demonstrated large segmental LOH of chromosome 13 in a subset of patients with FLT3/ITD 
(those with high ITD-AR)(60)  The region of LOH extended from regions centromeric to FLT3 and included 
the entire 13q telomeric to FLT3.  This large region of 13qLOH was limited to FLT3/ITD samples and was not 
observed in those with FLT3/ALM or those with FLT3/WT, suggesting a causal association between FLT3/ITD 
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and 13qLOH.  Further evaluation of copy numbers in those with 13qLOH demonstrated no copy number 
alterations (no deletion), demonstrating that the observed allelic variation is due to copy neutral LOH, otherwise 
referred to as acquired segmental uniparental disomy (aUPD).  Recent studies have demonstrated the presence 
of aUPD in not unique to FLT3/ITD and that aUPD may be a common event in myeloid pathogenesis.(61-65) 
Acquired segmental UPD is a mechanism by which a homozygous state is achieved after an initial acquisition 
of a heterozygous mutation, where the mutant allele is used as a template, and the wild type allele is converted 
to that of the mutant one, resulting in a homozygous state. We have demonstrated that in FLT3/ITD specimens 
with previously demonstrated 13q aUPD, CD34+/CD33- early myeloid progenitors exhibit FLT3/ITD in a 
heterozygous state (no aUPD), and homozygous state is observed only in the more mature, CD34+/CD33+ 
myeloid blasts, confirming that aUPD is a late event in the pathogenesis of AML.(60) Segmental UPD may 
involve a region within the allele resulting from two symmetrical break followed by repair, resulting in 
conversion of an intestitial region within the chromosome (interstitial segmental UPD, Figure 2C) or from a 
single break, leading to conversion of the entire telomeric segment of the chromosome (terminal segmental 
UPD, Figure 2D). 
 
Therapeutic Interventions in Patients with FLT3 Mutations. 
 Identification of FLT3 mutations in AML has raised the potential for its utility as molecular marker for 
risk-based therapy and the utility of the FLT3 mutation for targeting with novel small molecular inhibitors.  
There are now a number of studies available that have examined allogeneic hematopoietic cell transplantation 
(HCT) and novel small molecular inhibitors in patients harboring FLT3 mutations.  We will review the data on 
the role of HCT as well as the utility of FLT3 inhibitors in the management of patients with high-risk FLT3 
mutations.   
 
Role of HCT in FLT3/ITD+ AML. 
  AML patients with FLT3/ITDs have lower CR rates as those without FLT3/ITD, however, those who 
achieve a CR remain at significantly higher risk of relapse and death.(24, 27, 28, 66) Post-remission 
intensification therapies including allogeneic stem cell transplantation has been evaluated for its role in the 
treatment of AML patients with FLT3/ITDs.   A recent study examined whether patients who received 
allogeneic HCT in initial CR had an improved clinical outcome compared to those who were treated with 
conventional chemotherapy.(67)   Those patients with FLT3/ITDs who received an allogeneic HCT from a 
matched related donor had a lower RR (22% vs. 49%) than those patients who received standard chemotherapy.   
More recent adult and pediatric studies confirmed these finding by demonstrating that patients with FLT3/ITD 
benefited from allogeneic HCT in first CR.(28, 68) Therefore, the overall results suggest that although 
FLT3/ITDs are predictive of relapse and poor outcome in the chemotherapy setting, its prognostic significance 
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may be abrogated with allogeneic HCT.  This improvement in clinical outcomes with allogeneic transplantation 
for FLT3/ITD positive AML is very similar to the situation found for Philadelphia positive ALL where disease 
is associated with dismal outcome with chemotherapy alone, but not so with allogeneic HCT.  
 
Small Molecule Inhibitors as Therapeutic Options 
 The FLT3 pathway is an obvious target for tyrosine kinase inhibitors (TKIs), as FLT3 mutations are one 
of the most common mutations in AML and constitutively activate the receptor kinase.  Since over-expression 
of FLT3-WT and expression of FLT3 mutations have been implicated in leukemogenesis, small molecule 
inhibitors that block the constitutive activation of the mutated and even wild-type receptor may have therapeutic 
implications.(69) Initial in vitro studies using nonspecific TKIs (herbimycin A, AG1296, and AG1295) found 
that these drugs blocked constitutive activation of FLT3/ITDs and preferentially killed cells harboring 
FLT3/ITDs.(70-73)  Subsequent screens identified numerous other potential compounds (MLN518, PKC412, 
SU5416, SU5614, SU11248, CEP-701, CEP-5214) that also block FLT3 activation.  
 
Two compounds (CEP-701 and PKC-412) have demonstrated some therapeutic promise for AML 
patients with FLT3 mutations. CEP-701 (Lestaurtinib) is an indolocarbazole compounds that inhibits 
autophosphorylation of the WT and mutant FLT3 receptors (74, 75) with high selectivity against FLT3 
compared to other RTKs such as KIT, FMS, and PDGF.(74)  A phase I/II trial evaluated single agent CEP-701 
in patients with refractory, relapsed, or poor risk AML expressing FLT3-activating mutations.(76, 77)  Five of 
fourteen AML patients with FLT3 mutations achieved an objective clinical response with CEP-701 although no 
CRs were observed.(76, 77)   They also demonstrated that CEP-701 is highly plasma protein bound and lack of 
FLT3 inhibition in some instances may be due to lack of drug availability.(78, 79)  In evaluating the in vitro 
efficacy of CEP-701 in FLT3/ITD, Levis et al. demonstrated that CEP-701 combined with chemotherapy killed 
cell lines harboring a FLT3/ITDs in a synergistic fashion,(79) suggesting a possible therapeutic benefit to 
adding CEP-701 with chemotherapy. They subsequently evaluated the efficacy of combining CEP-701 
conventional chemotherapy.(78) A total of 48 AML patients with FLT3 mutations were randomized to either 
receiving standard chemotherapy or standard chemotherapy with CEP-701 during first relapse.  Of the 24 
patients who received CEP-701, 5 achieved complete CR and another 5 obtained a CR with incomplete count 
recovery. For those patients receiving only standard chemotherapy, 3 achieved CR and an additional 3 obtained 
CR with incomplete count recovery.  CEP-701 is also being evaluated in a phase III trial for its efficacy in de 
novo AML with FLT3 mutations in MRC 15, where patients with FLT3 mutations are randomized to standard 
chemotherapy with or without CEP-701.   
PKC412 (Midostaurin) is a benzoylstaurosporine, which was initially developed as a VEGF receptor 
inhibitor but also inhibits FLT3 receptor kinase.(80)  A phase II trial examined PKC412 as a single agent in 20 
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high risk AML patients with FLT3/ITDs.  Although 6 patients demonstrated objective response, again no CRs 
were observed.(81) The also observed that autophosphorylation of the mutant receptor was blocked in most of 
the responding patients, indicating an in vivo target response using the dose in the study.(81)  Subsequently, 
PKC-412 was combined with daunorubicin and cytarabine in 40 patients with de novo AML.(82)  The CR rate 
for those patients with FLT3-WT was 69% compared to >90% for those patients with FLT3 mutations, 
suggesting possible therapeutic advantage in patients with FLT3/ITDS for combining PKC412 with standard 
chemotherapy. A recent phase III study is randomizing 514 patients with de novo AML to daunorubicin, 
cytarabine, with or without PKC-412 in order to define the clinical efficacy of this combination therapy. 
These data suggest that FLT3 inhibitors as a single agent has a limited role in the treatment of AML, 
although their addition to conventional chemotherapy may provide therapeutic benefit for patients with 
FLT3/ITDs and perhaps other molecular alterations. Given the biological and clinical heterogeneity of FLT3 
mutations, future studies will need to determine which AML patients with FLT3 mutations have the highest 
likelihood to respond to these novel drugs in order to appropriately target agents to those patients who are most 
likely to benefit.  
 
Summary 
 Since the discovery of FLT3 mutations in 1996, there has been significant interest in examining the 
molecular biology and clinical significance of these mutations.  The current data suggest that FLT3 mutations 
are not sufficient for leukemic transformation and it requires other cooperating genomic alterations for 
evolution of leukemic phenotype.  In addition, the biology of these mutations is quite complex, with significant 
heterogeneity of the mutation type (ITD vs. ALM), expression level, size and allelic ratio, which impacts its 
biology and clinical response.  With evolving data on acquisition of LOH in patients with FLT3/ITD, it appears 
that clonal evolution of cells with FLT3/ITD may lead to homozygous state (aUPD) and impact disease biology 
and clinical outcome.  In fact there is evolving data that aUPD may be a more common event than previously 
recognized in the evolution of AML.  Our expanded knowledge into the genetic variability of FLT3 has 
emphasized the extent of the complexity in AML.   Further understanding of how such genomic complexities 
impact signal transduction would enable more appropriate targeting of the signal transduction pathway. 
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Figure 1.  FLT3 signal transduction pathway:  FLT3 receptor monomer is composed of an extracellular domain 
(ECD), a transmemberane domain (TMD), a Juxtamembrane domain (JMD) and a tyrosine kinase domain (TKD) 
interrupted by a short kinase insert.  Binding to FLT3 ligand (FL) leads to receptor dimerization and activation of the 
intracellular kinase.  Tyrosine kinase activation leads to phosphorylation of multiple sites in the intracellular kinase 
moiety. The activated receptor recruits a number of proteins in the cytoplasm including SHC and GRB2 to form a 
complex of protein-protein interactions, leading to activation of a number of intracellular mediators including AKT, 
MAPK and STAT.  Activated mediators interact with HSP90 which protects them from inactivation and chaperones 
the active mediators to the nuclear interphase, where they are released into the nucleus and act to mediate vital 
cellular functions including cell growth, differentiation, apoptosis, DNA repair and proliferation. 
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Figure 2. Loss of heterozygosity (LOH) as a due to aUPD.  Acquired uniparental disomy, resulting in homozygous state can 
involve the entire chromosome or be confined to a segment of a chromosome (Segmental aUPD).  Segmental aUPD is 
mediated through homologous recombination mediated somatic crossing over between two homologous non-sister chromatids.   
In baseline, non mutated state, genes are represented by two different alleles (A, heterozygous state).  Molecular alteration is 
acquired in one allele, leading to a heterozygous mutation (B).  Evolution of UPD leads to conversion of the wild type allele to 
mutant, and evolution of homozygous mutation. When interstitial, the segmental UPD results from two symmetrical breaks 
flanking a segment of the chromosome, where during repair process, the region flanked by the breaks in the wild type allele is 
used as a template and as a result, a segment of chromosome undergoes conversion from heterozygous to homozygous state 
(acquired UPD). Terminal segmental UPD results from a single symmetrical break in each of two homologous non-sister 
chromatids and the resultant repair product demonstrates UPD (LOH) of the region telomeric to the region of double strand 
break. 
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